• Read more about Oral 3D Stent

Short Title: Oral 3D Stent

The primary objective of this randomized trial is to evaluate the acute mucositis rates in non-target mucosa of patients who receive head and neck radiation with or without a customized 3D printed oral stent.

Study Number:

2020-1153

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04870762

Disease:

• Head and Neck Carcinoma

Study Phase:

Not Applicable

ResearchCancer@CooperHealth.edu

Index Extra:

Head and Neck

Hide from Search:

Off

Physician Name:

• Megan Mezera, MD

Department:

• Radiation Oncology

• Read more about GY019

Short Title: GY019

This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.

Study Number:

GY019

Study Status:

Enrolling

Treatment Agent:

Carboplatin, Letrozole, Paclitaxel

Resources and Links

National Clinical Trial Identified Number: NCT04095364

Disease:

• Low-Grade Serous Carcinoma of the Ovary, Fallopian tube, or Peritoneum

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• David P. Warshal, MD, FACOG

Department:

• Gynecologic Cancer Center

• Read more about Bone Sarcoma

Short Title: PA14-1067

The objectives of the study are to better understand the role of genomic alterations in bone sarcoma patients whose cancers have either progressed on therapy, after a period of response, or were refractory to initial "first-line" treatment.

Study Number:

PA14-1067

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Bone Sarcoma

Study Phase:

Not Applicable

ResearchCancer@CooperHealth.edu

Index Extra:

Bone, Orthopedic

Hide from Search:

Off

Physician Name:

• Tae Won B. Kim, MD

Department:

• Bone and Joint Institute,
• Surgical Oncology,
• Orthopaedic Oncology,
• Rare Cancers Program

• Read more about Guidance

Short Title: Guidance

This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy).

Study Number:

GU010

Study Status:

Enrolling

Treatment Agent:

Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide

Resources and Links

National Clinical Trial Identified Number: NCT05050084

Disease:

• Prostate Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

Prostate, GU

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about PREDICT-RT

Short Title: PREDICT-RT

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score.

Study Number:

GU009

Study Status:

Enrolling

Treatment Agent:

Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide

Resources and Links

National Clinical Trial Identified Number: NCT04513717

Disease:

• Prostate Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

GU, Prostate

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about High-Risk Colorectal Cancer Registry Program

The purpose of this registry is to create and maintain a prospective and retrospective database of patients with early-onset colorectal cancer or who are at increased risk for colorectal cancer based on germline gene mutation status, personal history of cancer, and/or family history of cancer.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Colorectal Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

GI, Colorectal, gastro

Hide from Search:

Off

Physician Name:

• Steven J McClane, MD, FACS, FASCRS

Department:

• Hematology and Medical Oncology

• Read more about High-Risk Breast Cancer Registry

The purpose of this registry is to collect data on patients at high risk for breast cancer or who have been diagnosed with breast cancer at MD Anderson Cancer Center at Cooper. The importance of the registry is to create a single institution database of individuals (men or women) at increased risk for developing breast cancer or individuals who have had a prior history of breast cancer. The data provided by a site-specific cancer registry can play a significant role in future planning of cancer control programs, in screening and early detection, and in contributing to improved breast cancer care.

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: N/A

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Catherine E. Loveland-Jones, MD, MS, FACS

Department:

• Breast Cancer Center

• Read more about Financial Toxicity

Short Title: Financial Toxicity

This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery. Post-mastectomy reconstructive patients are at high risk for financial toxicity (adverse effects of escalating health care cost on well-being). 

Study Number:

PA18-1077

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04169542

Disease:

• Breast Cancer

Study Phase:

Not Applicable

ResearchCancer@cooperhealth.edu

Index Extra:

breast

Hide from Search:

Off

Physician Name:

• Steven C. Bonawitz, MD, FACS

Department:

• Plastic and Reconstructive Surgery,
• Breast Cancer Center

• Read more about Celestimo

Short Title: Celestimo 

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.

 

Study Number:

GO42909

Study Status:

Enrolling

Treatment Agent:

Mosunetuzumab (BTCT4465A, RO7030816), Lenalidomide, Rituximab, Tocilizumab

Resources and Links

National Clinical Trial Identified Number: NCT04712097

Disease:

• Relapsed or Refractory Follicular Lymphoma

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

Lymphoma, HEM

Hide from Search:

Off

Physician Name:

• Tulin Budak-Alpdogan, MD

Department:

• Hematology and Medical Oncology